Transplantation outcome
. | Value . |
|---|---|
| Alive/dead, n | 69/55 |
| Median follow-up for survivors, d (range) | 565 (82-2217) |
| Cause of death | |
| Progression, n | 17 |
| Median days after transplantation (range) | 165 (2-1106) |
| Death without progression, n | 36 |
| Median days after transplantation (range) | 72 (8-718) |
| GVHD, n | 10 |
| Infection, n | 9 |
| IP, n | 6 |
| VOD, n | 3 |
| Renal failure, n | 2 |
| ARDS, n | 2 |
| Others: pericarditis, hemorrhage, cerebral infarction, RRT, n | 4 |
| Not described, n | 2 |
| Disease progression, n | 26 |
| Median days after transplantation (range) | 109 (0-1079) |
| Engraftment, n | |
| Engraftment | 115 |
| Rejection | 2 |
| Death within 20 days | 7 |
| Acute GVHD, n* | |
| Grade 0 | 31 |
| Grade I | 37 |
| Grade II | 30 |
| Grade III | 7 |
| Grade IV | 10 |
| Chronic GVHD, n† | |
| None | 47 |
| Limited | 17 |
| Extensive | 24 |
| Not described | 5 |
. | Value . |
|---|---|
| Alive/dead, n | 69/55 |
| Median follow-up for survivors, d (range) | 565 (82-2217) |
| Cause of death | |
| Progression, n | 17 |
| Median days after transplantation (range) | 165 (2-1106) |
| Death without progression, n | 36 |
| Median days after transplantation (range) | 72 (8-718) |
| GVHD, n | 10 |
| Infection, n | 9 |
| IP, n | 6 |
| VOD, n | 3 |
| Renal failure, n | 2 |
| ARDS, n | 2 |
| Others: pericarditis, hemorrhage, cerebral infarction, RRT, n | 4 |
| Not described, n | 2 |
| Disease progression, n | 26 |
| Median days after transplantation (range) | 109 (0-1079) |
| Engraftment, n | |
| Engraftment | 115 |
| Rejection | 2 |
| Death within 20 days | 7 |
| Acute GVHD, n* | |
| Grade 0 | 31 |
| Grade I | 37 |
| Grade II | 30 |
| Grade III | 7 |
| Grade IV | 10 |
| Chronic GVHD, n† | |
| None | 47 |
| Limited | 17 |
| Extensive | 24 |
| Not described | 5 |
GVHD indicates graft-versus-host disease; IP, interstitial pneumonitis; VOD, venoocclusive disease; ARDS, acute respiratory distress syndrome; RRT, regimenrelated toxicity.
Acute GVHD was evaluated among patients who achieved engraftment and survived more than 20 days after transplantation.
Chronic GVHD was evaluated among patients who survived more than 100 days after transplantation.